無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

市場アクセスへの影響 (EU5ヶ国):2型糖尿病 (経口薬)

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

発行 FirstWord 商品コード 593153
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
市場アクセスへの影響 (EU5ヶ国):2型糖尿病 (経口薬) Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018
出版日: 2018年04月01日 ページ情報: 英文
概要

当レポートでは、欧州主要5ヶ国 (EU5) で2型糖尿病の治療に従事している医療専門家150名に対するアンケート調査の結果に基づいて、糖尿病の治療薬 (経口薬) の調達・使用に関する問題点について分析し、基本的な市場構造や主要企業・ブランドの市場シェア、各社が現在直面している主な障害 (市場アクセスなど)、障害の主な要因 (各種規制ほか)、取るべき対応策といった情報を取りまとめてお届けいたします。

2型糖尿病 (T2DM) の治療用の主な経口薬

  • Forxiga (dapagliflozin; AstraZeneca)
  • Glyxambi (empagliflozin/linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Invokana (canagliflozin; Janssen Cilag)
  • Januvia (sitagliptin; Merck Sharp & Dohme)
  • Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
  • Onglyza (saxagliptin; AstraZeneca)
  • Qtern (saxagliptin/dapagliflozin; AstraZeneca)
  • Trajenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Vipidia (alogliptin;Takeda)

目次

  • 「市場障壁」とは何か?
  • 当レポートについて
  • 今回の分析について
  • 調査対象のブランド
  • エグゼクティブサマリー
目次

Market barriers affect a fifth of oral diabetes treatment prescriptions in Europe. Is your brand losing out?

Market barriers affect over a fifth of all oral type 2 diabetes mellitus (T2DM) prescriptions in Europe, and certain brands are losing out on market share big time. Is it yours? Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (EU5) [2018].

Based on a survey of 150 European diabetologists from the leading EU5 markets (France, Germany, Italy, Spain, and the UK), the report covers 9 major oral therapies from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Janssen Cilag, Merck Sharp & Dohme, and Takeda. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect just over a fifth of all prescriptions. Small, perhaps, but brands are still losing out on market share opportunities because of them. is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • One brand sees a robust share increase. Is this lead too big for the chasing pack to overcome? Is your brand leading, or are you in the chasing pack?
  • Two brands see a significant loss. Could market share losses be due to low prescribing rates, or is some other market dynamic at play? And perhaps most importantly, can this be prevented?
  • Eliminating barriers would have limited impact. Due to the overall barrier impact being 20 percent, eliminating barriers would have limited impact on market share performance.
  • Perception is a huge problem. Across all but one of the brands, a certain proportion of physicians have never heard of the treatment. Could improved physician education be the key to better market shares?

Insight into 9 Oral Type 2 Diabetes Mellitus Treatments

  • Forxiga (dapagliflozin; AstraZeneca)
  • Glyxambi (empagliflozin/linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Invokana (canagliflozin; Janssen Cilag)
  • Januvia (sitagliptin; Merck Sharp & Dohme)
  • Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
  • Onglyza (saxagliptin; AstraZeneca)
  • Qtern (saxagliptin/dapagliflozin; AstraZeneca)
  • Trajenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Vipidia (alogliptin; Takeda)

Exploring Market Access Barriers

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) explores key issues affecting type 2 diabetes mellitus drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 diabetologists and primary care physicians-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with type 2 diabetes mellitus in total in the last month

We conducted the survey between April 5-10, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Table of Contents

1. What are market barriers?

2. About this report

3. About the survey

4. Brands included in the survey

5. Executive summary

Back to Top